Effects of Serial locoregional application of water-filtered infrared a radiation in patients with systemic sclerosis and raynauds' Syndrom of the hands

Effects of Serial locoregional application of water-filtered infrared a radiation in patients with systemic sclerosis and raynauds' Syndrom of the hands - wiRASSc

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00021098

Enrollment

Registered

2020-03-18

Start date

2020-03-01

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

M34.0

Interventions

Group 1: Patients with SSc diagnosed according to the ACR/EULAR classification criteria of 2013 with Raynaud's syndrome of the hands, who in addition to the multimodal standard therapy receive an addi

Eligibility

Sex/Gender

All

Age

18 Years to 80 Years

Inclusion criteria

Inclusion criteria: Patients with systemic sclerosis who meet the ACR/EULAR classification criteria of 2013 and have Raynaud's syndrome of the hands, are able to speak German, are able to give consent and sign the informed consent form

Exclusion criteria

Exclusion criteria: Acute infections of the hands / fingers. Heat intolerance

Design outcomes

Primary

Measure	Time frame
Pain in the hands (VAS 0-100mm) after intervention / non-intervention	—

Secondary

Measure	Time frame
-Pain in the hands (VAS 0-100mm) after 2 weeks of successful/completed therapy -Tension feeling/ Tensed feeling/ Tensed sensation/ Stiffness of the hands (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy -Severity of Raynaud's attacks (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy -Length of Raynaud's attacks (in minutes) i) immediately after and ii) 2 weeks after therapy -General satisfaction with hands (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy - Satisfaction with general well-being (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy -Extent of difficulties in everyday life caused by SSc (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy - Extent of quality of life reduction by SSc (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy -Evaluation of the success of the wIRAS therapy i) immediately after and ii) 2 weeks after therapy -Evaluation of the success of all therapeutic measures i) immediately after and ii) 2 weeks after therapy -Measurement of hand force/ power i) immediately after therapy -Functionality (HAQ, FFbH) i) immediately after and ii) 2 weeks after therapy -CO2 measurements (relative blood flow and post-capillary oxygen saturation) on the index and ring finger of the hand i) immediately after and ii) 2 weeks after therapy - change in levels of molecular parameters of angiogenesis (VEGF, PDGF)	—

Measure

Time frame

-Pain in the hands (VAS 0-100mm) after 2 weeks of successful/completed therapy -Tension feeling/ Tensed feeling/ Tensed sensation/ Stiffness of the hands (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy -Severity of Raynaud's attacks (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy -Length of Raynaud's attacks (in minutes) i) immediately after and ii) 2 weeks after therapy -General satisfaction with hands (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy - Satisfaction with general well-being (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy -Extent of difficulties in everyday life caused by SSc (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy - Extent of quality of life reduction by SSc (VAS 0-100mm) i) immediately after and ii) 2 weeks after therapy -Evaluation of the success of the wIRAS therapy i) immediately after and ii) 2 weeks after therapy -Evaluation of the success of all therapeutic measures i) immediately after and ii) 2 weeks after therapy -Measurement of hand force/ power i) immediately after therapy -Functionality (HAQ, FFbH) i) immediately after and ii) 2 weeks after therapy -CO2 measurements (relative blood flow and post-capillary oxygen saturation) on the index and ring finger of the hand i) immediately after and ii) 2 weeks after therapy - change in levels of molecular parameters of angiogenesis (VEGF, PDGF)

—

Countries

Germany

Contacts

Public ContactPhilipp Klemm

Campus Kerckhoff der Jusuts-Liebig-Universität Gießen, Abteilung für Rheumatologie, Immunologie, Osteologie und Physikalische Medizin

p.klemm@kerckhoff-klinik.de06032-996-2101

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026